Erythropoietin is a hematopoietic cytokine that regulates the production of red blood cells. Erythropoietin is normally produced in the adult kidney in a hypoxia-inducible manner. The recombinant form of human erythropoietin is in clinical use for the prevention and treatment of anemia that is associated with cancer and its treatment with chemoradiation therapy. A series of recent studies from our laboratory and others have reported the expression of receptors for erythropoietin in several different types of human cancer cells. In the present study, we investigated the expression of erythropoietin receptor and its ligand erythropoietin in human prostate cancer. In clinical specimens of prostate cancer, we found abundant expression of erythropoietin receptor protein in all primary tumors examined using immunohistochemistry. Furthermore, we observed erythropoietin coexpression in prostate cancer cells by immunohistochemical analysis. To determine whether monolayer cultures of continuous cell lines derived from prostate cancer also express erythropoietin receptor and erythropoietin, we studied well-characterized hormone-responsive (LNCaP) and hormone-refractory (PC-3) prostate cancer cell lines. We performed reverse-transcription and polymerase chain reaction assays to detect erythropoietin receptor and erythropoietin mRNA transcripts, and also immunoprecipitation and immunoblotting to detect erythropoietin receptor protein expression in prostate cancer cells. These experiments revealed the expression of both erythropoietin receptor and erythropoietin in LNCaP and PC-3 cells suggesting that these prostate cancer cell lines may serve as useful experimental models for further studies of erythropoietin and erythropoietin receptor function in prostate cancer. The coexpression of erythropoietin receptor and its ligand erythropoietin in human prostate cancer cells suggests the potential for growth regulation by erythropoietin-erythropoietin receptor in an autocrine or paracrine manner.
Erythropoietin is a glycoprotein hormone that is the principal regulator of red blood cell production in mammals. 1 The primary sites of physiologic, hypoxia-inducible erythropoietin production include the fetal liver and adult kidney. 2 The ability of the recombinant form of human erythropoietin to stimulate the production of red blood cells has led to its widespread clinical use in patients with various chronic diseases that are associated with anemia, such as cancer. 3 The biologic effects of the hematopoietic cytokine erythropoietin require its binding to its specific transmembrane receptor erythropoietin receptor expressed in erythroid cells. [4] [5] [6] The interaction of erythropoietin with its cell surface receptor induces a conformational change of receptor homodimers leading to the activation of intracellular signal transduction that mediates the ability of erythropoietin to support the proliferation, terminal differentiation and survival of erythroid cells. 7, 8 Several previous studies have provided evidence for the presence of a functional erythropoietinerythropoietin receptor system in nonhematopoietic cell types and organs. For instance, the expression of erythropoietin receptor in vascular endothelial cells and neurons is associated with diverse physiological effects of erythropoietin that are distinct from its regulatory function in erythropoiesis. [9] [10] [11] In the brain where neurons express erythropoietin receptor and astrocytes express erythropoietin in a hypoxiainducible manner, erythropoietin was shown to protect against neuronal injury associated with ischemia. [12] [13] [14] [15] In the uterus, erythropoietin-erythropoietin receptor function was shown to be involved in the regulation of cyclic uterine angiogenesis. 16 In another example of the diverse nonhematopoietic biological effects of erythropoietin-erythropoietin receptor, our recent studies have shown that erythropoietin is a cytokine that promotes angiogenesis and modulates the physiologic wound-healing cascade. 17 A series of recent reports have described the expression of erythropoietin receptor and erythropoietin in several different types of human cancer cells. [18] [19] [20] In the present study, our objective was to determine whether human prostate cancer cells express the erythropoietin receptor and its ligand erythropoietin. We examined clinical specimens of primary prostate cancer for expression of erythropoietin receptor and erythropoietin protein using immunohistochemistry. We also investigated the relationship between erythropoietin receptor and erythropoietin expression and tumor growth fraction and apoptosis indices. In addition, we explored erythropoietin receptor and erythropoietin expression in monolayer cultures of continuous prostate cancer cell lines to determine whether these cell lines may be useful for future studies of erythropoietinerythropoietin receptor biology in prostate cancer.
Materials and methods

Clinical Specimens of Prostate Cancer
Human prostate cancer specimens were obtained under a protocol approved by the Institutional Review Board at Duke University Medical Center. Samples came from a cohort of 18 previously untreated patients with an age range of 53-75 years old who underwent radical prostatectomy for prostatic adenocarcinoma between 1995 and 2000. Tumors were graded according to the Gleason method (by RTV) as illustrated in Table 1 . The prostate-specific antigen (PSA) level at diagnosis ranged from 4.7 to 20.1 ng/ml. Formalin-fixed paraffin-embedded tissue blocks were obtained from the archives for immunohistochemical studies.
Cell Cultures
Monolayer cultures of human cancer cells derived from cancer of the prostate (LNCaP and PC-3 cells) were obtained from American Type Culture Collection (ATCC) and maintained in cell culture at 371C in a humidified 5% CO 2 atmosphere in accordance with the instructions from ATCC (Rockville, MD, USA). Chinese hamster ovary (CHO) cells engineered to overexpress human erythropoietin receptor were described previously. 20 Immunohistochemistry Sections (4 mm in thickness) from each block were placed on glass slides. The primary antibodies used in immunohistochemical studies were:
Polyclonal, affinity purified, rabbit anti-human erythropoietin receptor antibody at a dilution of 1:50 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Polyclonal, affinity purified, rabbit antierythropoietin antibody at dilution 1:50 (H-162, Santa Cruz). 19, 21, 22 For erythropoietin and erythropoietin receptor staining, the sections were deparaffinized in Hemo-D, rehydrated in graded alcohols, subjected to endogenous peroxidase block in 3% H 2 O 2 and boiled in 10% citrate buffer for antigen retrieval. This was followed by blocking with 5% donkey serum (Jackson Immunoresearch Labs, West Grove, PA, USA). Slides were incubated with antierythropoietin receptor or antierythropoietin antibodies overnight at 41C, and then washed and incubated with biotinylated donkey anti-rabbit secondary antibodies (Jackson labs, 1:1000) at 371C for 25 min followed by another incubation for 25 min with avidin-biotin peroxidase complex (ABC Kit, Vector Labs, Burlingame, CA, USA). Finally the sections were developed with diaminobenzidine tetrahydrochloride (DAB) chromogen and counterstained with hematoxylin. Negative controls for the immunohistochemistry consisted of sections incubated with preimmune rabbit immunoglobulin and were negative for any reactivity. Cytoplasmic or membrane staining was considered positive and for each neoplasm both the percentage of cells that exhibited immunoreactivity as well as the intensity of the staining in tumor cells were taken into account by evaluating pathologist (KA). The percentage of tumor cells that exhibited no staining (0) or weak (1), moderate (2) or intense staining (3) was determined by microscopic examination and the immunoreactivity score was determined by calculating weighted mean of stain intensity using the following formula:
Weighted mean of stain intensity ¼
P
IntensityÂPercentage of cells Total percentage of cells for a maximum weighted mean staining intensity score of 3.00. MIB-1 labeling index was used as a marker of tumor growth fraction using an antibody from the murine MIB-1 hybridoma clone and the labeled streptavidin/biotin/peroxidase/diaminobenzidine tetrachloride (DAB) method (Biocare, Walnut Creek, CA, USA) with antigen retrieval by pressure-cooking in citrate buffer (DAKO, Inc., Carpinteria, CA, USA). Slides were counterstained with hematoxylin and tonsillar tissue (lymphoid hyperplasia) served as a control. For each tumor, percent of positive nuclei in at least 10 random high-power fields (mean of 400 cells per tumor) were counted, averaged and recorded as described previously. 23 Apoptotic indices were determined using the TUNEL method (TdT-FragELt kit, Oncogene, Boston, MA, USA). Pretreated slides were incubated in biotin-labeled/unlabeled deoxynucleotides containing TdT at 371C for 1.5 h. The biotinylated nucleotides were detected using a streptavidinhorseradish peroxidase conjugate and then reacted with diaminobenzidine, forming an insoluble brown-colored precipitate at the site of DNA fragmentation. Using light microscopy and assessing the degree of nuclear staining against a methyl green counterstain, slides were given a rank score of 0 (lowest apoptotic index), 1 or 2 (highest apoptotic index).
RNA Isolation, Analysis and Southern Blotting
We investigated for erythropoietin receptor expression in monolayer cultures of cancer cell lines derived from human prostate cancer. The availability of continuous cell lines that express erythropoietin receptor may facilitate further molecular and functional studies of erythropoietin receptor expression in prostate cancer using in vitro as well as in vivo experimental models. We used well-characterized prostate cancer cell lines including androgenresponsive (LNCaP) cells and androgen-refractory (PC-3) cell lines. Using total RNA isolated from the cells, we performed reverse transcription and polymerase chain reaction assays designed to detect erythropoietin receptor mRNA transcripts using oligonucleotide primers specific for the coding sequence of human erythropoietin receptor gene. Total RNA was isolated using the RNeasy kit from Qiagen (Valencia, CA, USA) according to the manufacturer's instructions. To eliminate residual genomic DNA, the RNA samples were subjected to Amplification Grade DNase I digestion (Invitrogen, Carlsbad, CA, USA). For erythropoietin receptor mRNA transcript expression, complementary DNA (cDNA) was synthesized using 2 mg total RNA in a 20 ml reaction containing 500 ng oligodT primer, 1 mM each dNTPs, 40 U RNase inhibitor, 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 10 mM DTT, 5 mM MgCl 2 and 50 U of Superscript II reverse transcriptase (Invitrogen). Negative control reactions were performed in which RNA but no reverse transcriptase was added. Following first-strand cDNA synthesis, RNase H digestion (Invitrogen) was carried out prior to PCR. For PCR amplification, 1 ml of cDNA was used in a 50 ml reaction containing 10 mM TrisHCl, 1.5 mM MgCl 2 , 50 mM KCl (pH 8. GGT AGG AGA AGC TGT AGT TG 3 0 . PCR was performed using Thermal Cycler PTC-100 (MJ Research, Waltham, MA, USA). In each PCR experiment, following an initial incubation at 951C for 2 min, the denaturation step was performed at 941C for 1 min, annealing step at 601C for 1 min and the extension step was at 721C for 1 min for 40 cycles. An extension step was performed at 721C for 10 min after the final PCR cycle. In each PCR experiment, a negative control reaction was performed with water. Positive control for erythropoietin receptor expression included using cDNA synthesized from RNA from primary human erythroblasts as described. 20 To detect erythropoietin mRNA transcript expression, we used 2 mg of total RNA using the OneStep reverse transcription-polymerase chain reaction kit with Qsolution (Qiagen) according to the manufacturer's instructions and 0.6 mM of each oligonucleotide primer-sense 5 0 ATC ACG ACG GGC TGT GCT GAA CAC 3 0 and anti-sense 5 0 GGG AGA TGG CTT CCT TCT GGG CTC 3 0 with sequential incubations at 501C for 30 min and 951C for 15 min, followed by PCR performed at 941C for 1 min, annealing step at 601C for 1 min and extension step was at 721C for 1 min for 40 cycles. The PCR products were separated in 1.8% agarose gels, and the specificity of the amplified PCR products was confirmed by Southern blot analysis by hybridization of the blots to a radiolabeled human erythropoietin receptor or erythropoietin cDNA probes as described. 20 
Immunoprecipitation and Immunoblotting
To prepare whole cell lysates, monolayer cultures of prostate cancer cells were grown to confluence in 10 cm tissue culture plates, washed twice with icecold phosphate-buffered saline and lysed in ice-cold buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10% glycerol, 5 mM EDTA, 10 mM NaF, 1% Triton X-100 supplemented with 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonylfluoride, 10 mg/ml aprotinin and 10 mg/ml leupeptin followed by centrifugation at 13 000 g for 20 min at 41C. The concentration of the soluble proteins in the supernatants was determined using Bio-Rad protein assay (Hercules, CA, USA). Immunoprecipitation using 2 mg rabbit polyclonal antihuman erythropoietin receptor antibody (Santa Cruz) was performed as described. 20 The immune complexes were collected by incubation with protein A-agarose beads (Roche, Indianapolis, IN, USA), washed four times in cell lysis buffer supplemented with fresh protease inhibitors, eluted by heating to 951C for 5 min in 2X Laemmli sample buffer and subjected to 8% sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were electrophoretically transferred to PVDF (Immobilon-P) membranes (Millipore, Bedford, MA, USA). The membranes were blocked in TBST (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.05% (v/v) Tween-20) containing 5% nonfat dry milk for 1-2 h with agitation at room temperature. Immunoblots were then incubated with primary antibody (C-20-1:1000) overnight in 41C with gentle rocking. Following a second incubation with horseradishperoxidase conjugated donkey anti-rabbit secondary antibodies (Pierce, Rockford, IL, USA), the immune complexes were detected using SuperSignal Chemiluminescent Substrate (Pierce) and visualized with autoradiography following a 2-5 min exposure to Kodak Biomax MR film.
Statistical Analyses
Linear regression was used to relate either erythropoietin receptor score or erythropoietin score to other variables, and the residuals were examined to determine that they were approximately normally distributed. Paired t-tests were used to compare scoring results in benign vs tumor glands. The analyses were performed using S-PLUS software MathSoft, Inc. (Seattle, WA, USA) and all P-values are for two-tailed tests with a significance level set at Po0.05.
Results
Erythropoietin and Erythropoietin Receptor are Expressed in Clinical Specimens of Prostate Cancer
Immunohistochemical staining of the prostate tumors was performed to investigate for erythropoietin and erythropoietin receptor expression. Representative photomicrographs are illustrated in Figure 1 and the immunohistochemistry data are summarized in Table 1 . Erythropoietin and erythropoietin receptor expression was observed in all samples analyzed in the study. Glandular epithelium in both tumor tissue and adjacent normal epithelium showed positive immunostaining for erythropoietin receptor (Figure 1 , panels a-d) and erythropoietin ( Figure 1 , panels e-h). A predominantly cytoplasmic pattern of staining for both erythropoietin and erythropoietin receptor was present in cancer cells, consistent with the immunoreactivity pattern that we and others have observed in other types of neoplasms that express erythropoietin and erythropoietin receptor. 18, 19, 24, 25 Erythropoietin receptor also showed membrane immunoreactivity in some of the neoplastic and host cells. In most of the sections, the intensely erythropoietin receptor stained neoplastic glands could clearly be identified infiltrating into their weakly reactive non-neoplastic counterparts. Most of the tumors exhibited moderate to intense erythropoietin receptor immunoreactivity (Figure 1 , panels a-d and Table 1 ). Erythropoietin receptor immunoreactivity also was observed in certain other cell types, most notably the endothelial cells of larger blood vessels and particularly the tumor macrophages which were strongly positive (not shown). Erythropoietin immunoreactivity was present in all tumors (Figure 1 , panels e-h and Table 1 ) and the adjacent normal or hyperplastic prostatic glands also exhibited expression of erythropoietin.
We performed statistical analyses to relate erythropoietin and erythropoietin receptor expression in prostate tumors to other parameters including cellular proliferation and apoptosis indices as determined by MIB-1 staining and TUNEL assays, respectively (Table 1) . In benign glands, the erythropoietin receptor score was significantly related to erythropoietin score in benign glands (P ¼ 0.0015 by linear regression). The erythropoietin receptor score in tumor showed similar significant association with the erythropoietin score in tumor (P ¼ 0.02 by linear regression). Interestingly, the erythropoietin receptor score in tumor was not significantly related to the additional variables of either erythropoietin or erythropoietin receptor in benign tissues (P40.5 by linear regression). In addition, both expression of erythropoietin receptor and erythropoietin was significantly higher in tumor glands than in benign glands (P ¼ 0.0033 and 0.048, respectively by t-test). In summary, the data indicate that erythropoietin receptor and erythropoietin are upregulated by tumor and are closely linked when considering the same tissue type, that is, benign or tumor glands, but there is no apparent linkage between benign and malignant glands with respect to either marker. There was no association between serum PSA and any of the erythropoietin receptor or erythropoietin scores (P40.03 by linear regression). Furthermore, there was no association between tumor erythropoietin receptor or erythropoietin and MIB-1 index, TUNEL apoptosis category or Gleason score in the tumor (P40.1 by linear regression).
Human Prostate Cancer Cell Lines Express Erythropoietin Receptor and Erythropoietin
As illustrated in Figure 2b , we found erythropoietin receptor mRNA transcript expression in both LNCaP and PC-3 cells. We then investigated for the expression of erythropoietin receptor protein in prostate cancer cell lines using immunoprecipitation (IP) and immunoblotting. Figure 3 illustrates the results of a representative experiment. As a positive control for IP, we used CHO cells engineered to stably express human erythropoietin receptor and observed expected B66 kDa immunoreactivity consistent with erythropoietin receptor protein expression (Figure 3, lane 1) and as negative control, CHO cells transfected with empty expression vector were used where the IP and immunoblotting did not yield any immunoreactivity ( Figure  3 lane 2) . In immunoprecipitates of both LNCaP and PC-3 cells, we detected immunoreactivity consistent with erythropoietin receptor protein expression in prostate cancer cells (Figure 3, lanes 3 and 4,  respectively) .
In clinical tissue specimens of prostate cancer, we found the coexpression of erythropoietin receptor and its ligand erythropoietin. In the next set of experiments, we investigated whether erythropoietin mRNA transcripts are expressed in LNCaP and PC-3 prostate cancer cell lines. Total RNA isolated from the cells was subjected to reverse transcriptionpolymerase chain reaction as described in Materials and methods. The reverse transcription-polymerase chain reaction products were separated by agarose gel electrophoresis and Southern blotting was carried out followed by hybridization to a specific radiolabeled erythropoietin cDNA probe. Figure 4 illustrates the results of a representative experiment in which erythropoietin expression was observed in both LNCaP and PC-3 cells and positive control HepG2 cells (lanes 1, 3 and 5 respectively). Negative control reverse transcription-polymerase chain reactions were performed without reverse transcriptase and using water in the PCR (Figure 4, lanes 2, 4 and  6 ). Taken together, our studies demonstrate the expression of erythropoietin receptor and erythropoietin in prostate cancer cells.
Discussion
Prostate cancer is a major health problem with an estimated 230 110 new cases and 29 900 deaths expected in the United States during 2004. 26 The majority of carcinomas that develop in the prostate are adenocarcinomas arising from the prostatic epithelium that initially occur as androgen-dependent tumors and often progress to tumors that are hormone-insensitive. Alterations in cellular androgen receptor expression or function have been implicated in prostate cancer progression. 27, 28 Prostate cancer cells also express nonsteroid cellular receptors which include transmembrane receptor protein tyrosine kinases such as the receptors for epidermal growth factor family and insulin-like growth factor. [29] [30] [31] [32] In the present study, we report the expression of the cytokine receptor erythropoietin receptor and its ligand the glycoprotein hormone erythropoietin in human prostate cancer cells.
The ability of erythropoietin to stimulate the production of red blood cells has led to the use of recombinant human erythropoietin for the prevention or treatment of anemia in cancer patients. 33 The benefits of recombinant human erythropoietin in patients with cancer-related anemia include increased hemoglobin levels, reduced transfusion requirements and improved quality of life. [34] [35] [36] [37] [38] In patients with prostate cancer, the presence of anemia may be associated with a significant reduction in survival. 39 In patients with hormone-refractory prostate cancer, serial measurements of hemoglobin provided as much, or more prognostic information as serial measurement of PSA. 40 Anemia was reported to develop in 81% of patients with prostate cancer after receiving neoadjuvant combined androgen blockade and pelvic radiotherapy. 41 In another study, combined hormonal blockade was associated with a significant decrease in hemoglobin in 90% of patients; this decline was related to the duration of treatment and recovered after treatment of symptomatic patients with recombinant human erythropoietin. 42 In a randomized study of patients with anemia and metastatic hormone-refractory prostate cancer, administration of higher doses of recombinant human erythropoietin was associated with increased hemoglobin, reduction of blood transfusions and improvement in quality of life compared to lower erythropoietin doses. 43 In another randomized study of anemic cancer patients, including those with prostate cancer undergoing radiotherapy, recombinant human erythropoietin administration was associated with a beneficial effect on hemoglobin levels. 44 It has been suggested in the literature that in patients with prostate cancer, recombinant human erythropoietin use may be justified prior to radical prostatectomy to reduce autologous blood transfusion risk as well as in anemic patients with advanced, hormone-refractory disease. 45, 46 However, in light of our findings, in patients with prostate cancer who may benefit from therapy with recombinant human erythropoietin, the expression of erythropoietin receptor in tumor cells may need to be taken into consideration in the design of future clinical trials.
Erythropoietin exerts its cellular effects by binding to its specific transmembrane receptor, the erythropoietin receptor, a member of the Type I cytokine receptor superfamily, characterized by the absence of intrinsic tyrosine kinase enzymatic activity. 47, 48 Expression of members of the cytokine receptor family other than erythropoietin receptor were previously reported in prostate cancer cells, such as the receptors for interleukin-6 49-51 and granulocyte-macrophage colony stimulating factor. 52, 53 Interleukin-6 has been shown to contribute to the growth of prostate cancer cells as an autocrine and paracrine factor 51 and to the activation of androgen receptor-dependent gene expression. 54 Similarly, recombinant human granulocyte-macrophage colony stimulating factor was found to stimulate the proliferation of LNCaP cells. 53 Whether or not erythropoietin may contribute to the growth of prostate cancer cells in a manner similar to interleukin-6 or granulocyte-macrophage colony stimulating factor remains to be determined. The coexpression of erythropoietin receptor and its ligand erythropoietin in prostate cancer cells suggests the potential for an autocrine and/or paracrine growth-promoting role for erythropoietin-erythropoietin receptor in prostate cancer.
Several recent studies from our laboratory as well as others have reported the expression of erythropoietin receptor and, in some cases erythropoietin, in primary neoplasms and tumor cell lines such as melanoma, breast, renal, ovarian, gastric and uterine cancers as well as pediatric tumors. [18] [19] [20] 24, [55] [56] [57] [58] [59] [60] [61] [62] In experimental animal models of cancer, disruption of erythropoietin-erythropoietin receptor signaling in tumors was associated with an antitumor effect in xenografts of human female genital tract cancers and melanoma 58, 61 and in a rodent syngeneic model of breast cancer. 19 The pathophysiologic role, if any, of erythropoietin receptor and erythropoietin coexpression in prostate cancer cells and whether exogenous recombinant erythropoietin may exert direct in vivo effects on tumor cells that express erythropoietin receptor remain to be determined. Our studies have shown the expression of erythropoietin receptor in monolayer cultures of hormonesensitive (LNCaP) and hormone-refractory (PC-3) cancer cell lines derived from human prostate cancer. These prostate cancer cell lines may be useful for future in vitro and in vivo studies of erythropoietin-erythropoietin receptor function in prostate cancer.
The efficacy and safety of recombinant human erythropoietin in cancer patients has been demonstrated in several randomized clinical trials involving large numbers of patients. 38, 63, 64 However, a randomized, prospective trial involving patients with metastatic breast cancer was terminated early due to impaired survival associated with disease progression in the recombinant erythropoietin arm compared to the placebo arm. 65 In another trial of patients with head neck cancer receiving radiation therapy only, poorer progression-free survival was reported in patients randomized to the recombinant human erythropoietin arm. 66 Given the results of our studies demonstrating the expression of erythropoietin receptor and its ligand erythropoietin in prostate cancer cells, further investigations of the biology of erythropoietin-erythropoietin receptor in prostate cancer are warranted.
